Cargando…

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

AIM: To determine the efficacy of rifaximin for hepatic encephalopathy (HE) with the linkage of gut microbiome in decompensated cirrhotic patients. METHODS: Twenty patients (12 men and 8 women; median age, 66.8 years; range, 46-81 years) with decompensated cirrhosis (Child-pugh score > 7) underwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaji, Kosuke, Takaya, Hiroaki, Saikawa, Soichiro, Furukawa, Masanori, Sato, Shinya, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Case Control Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743506/ https://www.ncbi.nlm.nih.gov/pubmed/29307995 http://dx.doi.org/10.3748/wjg.v23.i47.8355

Ejemplares similares

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis
por: Sato, Shinya, et al.
Publicado: (2020)

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B
por: Noguchi, Ryuichi, et al.
Publicado: (2017)

Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
por: Furukawa, Masanori, et al.
Publicado: (2021)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
por: Tsuji, Yuki, et al.
Publicado: (2020)

Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells
por: Kitagawa, Koh, et al.
Publicado: (2020)

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

Treatment of long-segment Barrett’s adenocarcinoma by complete circular endoscopic submucosal dissection: a case report
por: Kaneko, Miki, et al.
Publicado: (2018)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
por: Takagi, Hirotetsu, et al.
Publicado: (2021)

Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis
por: Murata, Koji, et al.
Publicado: (2022)

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats
por: Nishimura, Norihisa, et al.
Publicado: (2018)

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study
por: Kitagawa, Koh, et al.
Publicado: (2022)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
por: Akahane, Takemi, et al.
Publicado: (2020)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease
por: Tahara, Kazuki, et al.
Publicado: (2019)

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis
por: Ogawa, Hiroyuki, et al.
Publicado: (2021)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2023)

Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
por: Asada, Shohei, et al.
Publicado: (2017)

Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
por: Nishimura, Norihisa, et al.
Publicado: (2021)

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
por: Seki, Kenichiro, et al.
Publicado: (2018)

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

Association between Equol Production Status and Nonalcoholic Steatohepatitis
por: Akahane, Takemi, et al.
Publicado: (2021)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria
por: Takaya, Hiroaki, et al.
Publicado: (2021)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases
por: Takaya, Hiroaki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hc9eovo1i3djpkhch32v8ck8ug